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OBJECTIVES The purpose of this study was to assess the clinical and angiographic benefits of elective
stenting in coronary arteries with a reference diameter of 2.1 to 3.0 mm, as compared with
traditional percutaneous transluminal coronary angioplasty (PTCA).
BACKGROUND The problems related to small-vessel stenting might be overcome using modern stents
designed for small vessels, combined with effective antiplatelet therapy.
METHODS In five centers, 145 patients with stable or unstable angina were randomly assigned to elective
stenting treatment with the heparin (Hepamed)-coated beStent or PTCA. Control angiog-
raphy was performed after six months. The primary end point was the minimal lumen
diameter (MLD) at follow-up. Secondary end points were the restenosis rate, event-free
survival and angina status.
RESULTS At follow-up, there was a trend toward a larger MLD in the stent group (1.69  0.52 mm
vs. 1.57  0.44 mm, p  0.096). Event-free survival at follow-up was significantly higher in
the stent group: 90.5% vs. 76.1% (p  0.016). The restenosis rate was low in both groups
(9.7% and 18.8% in the stent and PTCA groups, respectively; p 0.15). Analyzed as treated,
both the MLD and restenosis rate were significantly improved in patients who had stents as
compared with PTCA.
CONCLUSIONS In small coronary arteries, both PTCA and elective stenting are associated with good clinical
and angiographic outcomes after six months. Compared with PTCA, elective treatment with
the heparin-coated beStent improves the clinical outcome; however, there was only a
nonsignificant trend toward angiographic improvement. (J Am Coll Cardiol 2001;38:
1598–603) © 2001 by the American College of Cardiology
Elective stenting treatment in small coronary arteries is not
yet supported by randomized trials. Despite this, small-
vessel angioplasty constitutes nearly half of all stent proce-
dures in some centers (1,2). The relatively high incidence of
restenosis and early thrombosis reported after small-vessel
angioplasty (3) might be reduced by using second-
generation stents designed for small dimensions, combined
with modern antiplatelet therapy.
See page 1604
To investigate the potential benefit of elective stenting as
opposed to conventional percutaneous transluminal coro-
nary angioplasty (PTCA) in small arteries, we conducted
the Stenting In Small Coronary Arteries (SISCA) trial, a
randomized, controlled, multicenter study. The study device
chosen was the small beStent (Medtronic InStent, Minne-
apolis, Minnesota). To optimize the stenting treatment
maximally, we used a heparin-coated version (Hepamed,
Medtronic Bakken Research Center, Maastricht, The
Netherlands), developed exclusively for this trial.
METHODS
Patient selection. Eligible patients were those referred for
elective or immediate angioplasty, who had single-vessel or
multivessel disease, stable or unstable angina and no con-
traindications to the study medication. Angiographic inclu-
sion criteria were de novo in vessels with a reference
diameter (RD) of 2.1 to 3.0 mm, with a diameter stenosis
(DS) 50%, suitable for treatment with a single 15-mm
stent. Exclusion criteria were functionally occluded vessels,
vessels with multiple lesions or visible thrombus, bifurca-
tional lesions, vessels with patent grafts and ongoing myo-
cardial infarction. Multivessel and multistage angioplasty
was allowed. However, study inclusion was restricted to one
lesion per patient. The study was approved by the regional
Ethics Committee and conducted in compliance with the
Declaration of Helsinki. Oral and written, informed con-
sent was obtained from all patients.
Angioplasty and randomization. The patients were pre-
treated with aspirin, and heparin and glycoprotein IIb/IIIa
inhibitors were given according to local standards. A load-
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ing dose of ticlopidine (500 mg) or clopidogrel (300 mg)
was given immediately after the intervention. A central
office coordinated the randomization, which was stratified
per center and per treatment in a block design.
The small 15-mm beStent used in this study was coated
with Hepamed, a heparin-coating. The coating process and
properties were identical to those developed for the
Hepamed-coated Wiktor stent, as described in detail else-
where (4). The lower recommended expansion size of the
beStent was 2.3 mm, allowing vessels with a RD of
2.1 mm to be included, provided that the balloon/artery
(BA) ratio was 1.1. The stents were hand-crimped on the
appropriate balloon catheter.
High-pressure stent dilation was recommended, aiming
at a BA ratio of 1.1. Crossing over from balloon to stent
treatment was indicated if the final PTCA resulted in a
residual DS50%, or in case of impaired flow due to severe
dissection or thrombus formation. Post-procedural medical
treatment consisted of at least one-month continuation of
75 mg aspirin, supplemented by a thienopyridine for one
month in patients who had received a stent.
Quantitative coronary angiography. Angiographic inclu-
sion criteria were evaluated by on-line quantitative coronary
angiographic (QCA) analysis, displaying the target lesion
preferably in at least two near orthogonal angles. Adminis-
tration of 0.1 to 0.2 mg of intracoronary nitroglycerin
preceded angiographic runs acquired for QCA analysis.
Calibration was performed on the contrast-filled catheter.
The lesions were analyzed by the worst-view approach. The
BA ratio was calculated from the ratio of the largest inflated
RD of the balloon to the RD of the vessel. Angiographic
recordings were stored on film or compact disk according to
local equipment. Core laboratory analysis was performed by
HeartCore B.V. (Leiden, The Netherlands), using the
QCA-Cardiovascular Measurement System (CMS), ver-
sions 4.0 and 4.1, analysis packages (Medis, Leiden, The
Netherlands).
Follow-up. The patients were monitored for per and post-
procedure acute myocardial infarction by serial electrocar-
diograms and creatine kinase levels. The patients were
contacted after one month to assess clinical events and
functional angina class, according to the Canadian Cardio-
vascular Society (CCS) classification (5). After six months,
they were scheduled for clinical and angiographic control
studies. Angiograms obtained for clinical reasons before
four months were accepted for follow-up analysis provided
that the study lesion had reached an end point.
Study end points and definitions. The primary objective
of the study was to investigate the minimal lumen diameter
(MLD) at follow-up. Secondary angiographic end points
were the dichotomous restenosis rates, net gain and angio-
graphic and procedural success rates. The clinical end points
were the occurrence of major adverse cardiac events
(MACE), acute (24 h) and subacute (1 to 30 days) stent
thrombosis and clinical angina, according to the CCS and
Braunwald classifications of unstable angina (6) at follow-
up.
Cardiac death, acute myocardial infarction, target lesion
revascularization and target vessel revascularization com-
prised MACE. Angiographic success was defined as resid-
ual DS50% after the intervention. Procedural success was
present when angiographic success was achieved without
crossing over, and in the absence of in-hospital MACE.
Acute myocardial infarction was present when two of the
following three criteria were met: prolonged chest pain of
cardiac origin not relieved by nitroglycerin, a rise in creatine
kinase of more than twice the upper reference limit or new
Q waves on the electrocardiogram. Acute myocardial infarc-
tion related to closure of a nonstudy vessel was not consid-
ered as a MACE. Target vessel revascularization was
present when the culprit lesion of a repeat revascularization
was located outside the target lesion, but within the segment
instrumented by the guide wire at the index procedure.
Death was not considered as a MACE if the clinical setting
or an autopsy indicated a noncardiac cause. All events were
reviewed by an external Safety Board.
Restenosis was defined as DS 50% during follow-up.
The acute gain was the difference in MLD between post-
intervention and baseline; late loss was the difference in
MLD between post-intervention and follow-up; and net
gain was the difference in MLD between follow-up and
baseline. The acute-gain index, relative loss and net gain
index expressed the acute gain, late loss and net gain
normalized for vessel size, divided by the RD. Lesions were
characterized according to the modified American Heart
Association/American College of Cardiology classification
(7). Dissections were classified according to the criteria of
the National Heart, Lung and Blood Institute (8). Occlu-
sion was defined as Thrombolysis in Myocardial Infarction
(TIMI) flow grade 0 or 1 (9).
Statistical analysis. The sample size was calculated by
assuming 0.2 mm to be the difference of interest in mean
MLD between the two groups, with a standard deviation of
0.5 mm. Two hundred patients would be sufficient to detect
this difference, with a significance level of 5% and a power
of 80% (10). This sample size would also be sufficient to
detect a reduction in restenosis from 45% to 25%. Both
assumptions are supported by published data (11–13). The
results are presented as the mean value  SD. Continuous
variables were compared by using the Student t test or the
Abbreviations and Acronyms
BA  balloon/artery ratio
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Kruskal-Wallis test if the variables deviated significantly
from normal distribution, as judged by the Lilliefors version
of the Kolmogorov-Smirnov test. Frequencies were com-
pared by using the chi-square test or Fisher exact test, as
appropriate. Survival free of MACE was analyzed by means
of Kaplan-Meier survival curves, and the differences be-
tween the groups were assessed by the log-rank test. The
main analysis was based on the intention-to-treat principle.
RESULTS
Population characteristics. The SISCA study recruited
patients in five Scandinavian centers between February 1998
and November 1999. The protocol prescribed a total of 200
patients, but inclusion was terminated prematurely because
of expiration of the biologic activity of the heparin coating.
Hence, a total of 145 patients were included: 74 patients
assigned to stenting treatment and 71 patients assigned to
PTCA. No one was excluded from follow-up analysis. The
baseline clinical and angiographic characteristics are dis-
played in Tables 1 and 2. The groups were well matched.
In-hospital and one-month clinical outcomes. In the
stenting and PTCA groups, 3 (4.1%) and 10 patients
(14.1%), respectively, crossed over to the alternative treat-
ment modality. All patients who crossed over fulfilled the
criteria of angiographic success. An additional stent was
implanted in five lesions. Abciximab was administered in
two patients who underwent stenting and in six patients
who had PTCA.
Balloon size, balloon pressure and angiographic and
procedural success rates are shown in Table 2. Two patients
experienced events during the first month: one patient with
a stent, a protocol violator not receiving aspirin, developed
acute stent thrombosis. One patient who had PTCA suf-
fered from severe recoil on the first day, requiring a repeat
intervention. Creatine kinase release above the normal
reference level (250 IU), in the absence of chest pain or
Q-wave development, was found in one patient with a stent
(327 IU) and in two patients who had PTCA (269 and 529
IU).
Late clinical outcomes (day 30 to follow-up). Clinical
data at six-month follow-up were obtained for all patients
(Table 3). Survival free of MACE in the stent group was
significantly higher than that in the PTCA group. This
difference was also significant at day 150 (p 0.026), which
was before the scheduled angiographic control study. The
different outcome was generated by a higher rate of repeat
interventions. At follow-up, 91.9% of the patients in the
stent group had angina pectoris CCSII, as compared with
78.9% in the PTCA group (p  0.033 by the Fisher exact
test). In both groups, the improvement in functional angina
status was significantly different from the baseline status
(p  0.001 by the McNemar test). One patient who had
PTCA died of heart failure caused by cardiac amyloidosis,
displaying open coronary arteries on the control angiogram
and subsequent autopsy. There were no noncardiac deaths
and no acute myocardial infarctions related to occlusions of
nonstudy vessels. Table 3 shows the total number of clinical
end points.
Angiographic follow-up. Angiographic follow-up was
performed after 179  35 days, and follow-up QCA
Table 1. Baseline Clinical Characteristics
BeStent
(n  74)
Balloon
Angioplasty
(n  71)
Age (years) 63.1  11.2 62.7  10.1
Female 43.2% 26.7%†
Current smoker 20.3% 14.1%
Hypertension 41.9% 46.5%
Diabetes 12.2% 14.1%
Hypercholesterolemia 85.1% 81.7%
Statin treatment 74.3% 67.6%
Body mass index 26.8  4.6 26.8  3.7
Family history 47.9% 57.7%
Previous AMI 41.9% 45.1%
Previous angioplasty 14.9% 16.9%
Previous CABG 5.4% 12.7%
Multivessel disease 56.8% 57.7%
Multilesion intervention 39.2% 53.5%
Angina status
Stable angina 74.3% 78.9%
Silent ischemia 10.8% 4.2%
CCS class I 5.4% 7.0%
CCS class II 24.3% 28.2%
CCS class III 28.4% 35.2%
CCS class IV 5.4% 4.2%
Unstable angina* 25.7% 21.1%
Crescendo (IB) 5.4% 4.2%
Rest (IIB, IIIB) 12.2% 11.3%
Postinfarction (I–IIIC) 8.1% 5.6%
Ejection fraction 0.71  0.10 0.70  0.10
*Unstable angina according to the Braunwald criteria (6). †p  0.055 by the Fisher
exact test. Data are presented as the mean value  SD or percentage of patients.
AMI  acute myocardial infarction; CABG  coronary artery bypass graft
surgery; CCS  Canadian Cardiovascular Society (5).
Table 2. Lesion and Procedural Characteristics
BeStent
(n  74)
Balloon
Angioplasty
(n  71) p Value
Vessel territory (%)
LAD 37.8 39.4 NS
Cx 45.9 43.7 NS
RCA 16.2 16.9 NS
Lesion classification* (%)
Type A 13.7 11.6 NS
Type B1 43.8 58.0 NS
Type B2 42.5 30.4 NS
Lesion length (mm) 11.8  4.5 10.8  4.3 NS
Balloon/artery ratio 1.06  0.14 1.04  0.14 NS
Maximal balloon
pressure (atm)
13.3  2.8 10.6  0.33  0.001
Nominal balloon size (mm) 2.60  0.30 2.62  0.33 NS
Angiographic success (%) 100 95.8 NS
Procedural success (%) 94.6 80.3 0.011
*Lesion classification according to the American Heart Association/American College
of Cardiology (7). Data are presented as the percentage of patients or mean value 
SD.
Cx  circumflex artery; LAD  left anterior descending artery; NS  not
significant; RCA  right coronary artery.
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analysis was obtained in 141 patients (97.2%). The QCA
data are shown in Table 4. Intention-to-treat analysis
demonstrated that net gain was significantly larger (p 
0.022) and DS was significantly lower (p  0.025) in the
stent group than in the PTCA group. The MLD at
follow-up, however, did not improve significantly by stent-
ing (p  0.096). The restenosis rate in the stent group was
9.7%, as compared with 18.8% in the PTCA group (p 
0.15). Analysis of the main angiographic measurements,
based on de facto treatment (i.e., per-protocol approach),
showed significant differences between the stent-treated and
PTCA-treated patients: MLD 1.71  0.49 vs. 1.54 
47 mm (p  0.029); restenosis rate: 6.3% vs. 24.2% (p 
0.003), respectively.
DISCUSSION
The present trial has demonstrated that both PTCA and
elective stenting in small coronary arteries are associated
with good clinical and angiographic outcomes after six
months. Compared with PTCA, elective treatment with the
heparin-coated beStent improves the clinical outcome.
However, there was only a nonsignifcant trend toward
angiographic improvement by the intention-to-treat analy-
sis.
Clinical outcome. In general, angioplasty in small coro-
nary arteries was safe, with no deaths related to ischemic
heart disease and only two patients with acute myocardial
infarction. When comparing the two treatment modalities,
elective placement of the heparin-coated beStent provided
an even better result than did PTCA, with respect to the
clinical outcome. Survival free of MACE was significantly
higher in the stent group than in the PTCA group (90.5%
vs. 76.1%, p  0.016 by the log-rank test). Repeat inter-
ventions constituted the major part of these events and were
significantly less frequent in the stent group (9.6% vs.
23.2%, p  0.041). The Kaplan-Meier plot in Figure 1
shows that the curves diverge early. Already after 150 days
of follow-up (i.e., well before the scheduled angiographic
control study), MACE-free survival was significantly higher
in the stent group (p  0.026 by the log-rank test). This
finding is strongly suggestive of a true clinical benefit of
stenting, because the events before day 150 were clinically
driven and not initiated by the scheduled angiographic
control study.
Angiographic outcome. Intention-to-treat analysis of the
angiographic outcome at follow-up showed a significant
benefit of stenting, with respect to net gain and DS. For the
primary end point of MLD, as well as the restenosis rate,
Table 3. Major Adverse Cardiac Events
BeStent
(n  74)
Balloon
Angioplasty
(n  71) p Value
Death
First month 0 0
First month to follow-up 0 1
AMI
First month 1 0
First month to follow-up 0 1
Repeat revascularization
TLR first month 1 1
TLR first month to 6 months 6 12 0.13
TVR first month 0 0
TVR first month to 6 months 0 5 0.026
CABG during follow-up 1 2
Any repeat revascularization 7 (9.6%) 16 (23.2%) 0.041
MACE-free survival at 6 months* 90.5% 76.1% 0.016
*P values by Fisher exact test, except log-rank test. Data are presented as the number
of patients or percentage of study group.
AMI  acute myocardial infarction; CABG  coronary artery bypass graft
surgery; MACE  major adverse cardiac events; TLR  target lesion revasculariza-
tion; TVR  target vessel revascularization.
Table 4. Quantitative Coronary Angiographic Data
BeStent
(n  72)
Balloon
Angioplasty
(n  69) p Value
RD (mm)
Baseline 2.44  0.35 2.38  0.32 NS
Final 2.51  0.29 2.41  0.32 0.07
Follow-up 2.42  0.35 2.42  0.31 NS
MLD (mm)
Baseline 0.99  0.28 1.01  0.24 NS
Final 2.22  0.27 1.79  0.36 0.001
Follow-up 1.69  0.52 1.57  0.44 0.096
DS (%)
Baseline 59.4  9.9 57.4  8.9 NS
Final 11.3  8.0 25.3  13.0 0.001
Follow-up 29.8  18.1 35.1  17.2 0.025
Restenosis rate (%) 9.7% 18.8% 0.15
Acute gain (mm) 1.23  0.28 0.77  0.38 0.001
Acute gain index 0.52  0.14 0.33  0.16 0.001
Late loss (mm) 0.54  0.48 0.25  0.49 0.001
Relative loss 0.23  0.21 0.10  0.20 0.001
Net gain (mm) 0.72  0.52 0.55  0.42 0.022
Net gain index 0.30  0.21 0.23  0.17 0.033
The Kruskal-Wallis test was used for continuous variables, and the Fisher exact test
for proportion. Data are presented as the mean value  SD.
DS  diameter stenosis; MLD  minimal lumen diameter; RD  reference
diameter.
Figure 1. Kaplan-Meier plot of event-free survival (p  0.016 by the
log-rank test). Solid line  beStent; dashed line  balloon angioplasty.
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there was only a nonsignificant trend toward improvement
(Table 4). However, when analyzing these last two variables
in a per-protocol approach, a statistically significant differ-
ence in favor of stenting, as compared with PTCA, was
present. This might indicate that the analysis of MLD and
the restenosis rate in the present trial suffer from a type II
error in the intention-to-treat model. The improved event-
free survival in the stent group could support such an
interpretation.
Comparison with other trials. The remarkably low inci-
dence of restenosis in the present study differs from the
findings in the small vessel stent trial of Kastrati et al. (14),
in which the restenosis rates in the stent and PTCA groups
were 35% and 37%, respectively. Preliminary data from
other trials have also demonstrated higher restenosis rates
than those found in our study (1). This might be explained
by the clinical and lesion-specific characteristics of the
present study group. There was only one calcified lesion and
no type C lesions. Total occlusions were excluded. Further-
more, the pre-interventional DS was relatively low. Thus,
the lesions studied probably carried a low inherent risk of
relapse after angioplasty, facilitating good results.
The use of heparin-coated stents also distinguishes the
present study from similar ones. However, we have no data
to indicate that the Hepamed coating was responsible for
the low restenosis rate in the present trial. This is in
agreement with a study using another heparin coating (15).
In a recent report on provisional small-vessel stenting, we
also demonstrated a low restenosis rate using the uncoated
15- or 25-mm beStent in complex lesions (11). Therefore,
the design of the beStent may be more important than the
coating in terms of the outcome.
Aggressiveness. Finally, the stent implantation technique
itself might influence the outcome. Although “the bigger
the better” approach has been supported by numerous
reports, recent evidence of the detrimental effect of media
damage through aggressive angioplasty might challenge this
hypothesis (16,17). In the present study, a less aggressive
approach may have been used, as reflected by the modest
BA ratio (1.06) and the final DS of 11.3  8%. However,
high-pressure deployment was used, probably yielding suf-
ficient stent apposition in such discrete lesions. Careful
balloon sizing, avoiding overstretching of the vessel, may
therefore have contributed to the favorable results.
Study limitations. First, because the trial was terminated
prematurely, a type II error in statistical analysis might have
occurred. The near-complete follow-up may have compen-
sated, in part, for this limited sample size. Second, QCA
measurements may not reflect the true vessel dimensions,
because the method relies on the lumen size, rather than the
true vessel size. Its potential to detect diffuse disease, often
present in small vessels, is limited. Also, QCA does not
always detect the physiologic importance of a lesion. How-
ever, both the QCA-CMS system and the core laboratory
analysis are extensively validated (18). Finally, the protocol
restricted the inclusion to discrete lesions. Because the
present study is from the same group that conducted the
Stenting In Chronic Coronary Occlusion (SICCO) trial
(19), in which stenting in vessels2.5 mm was shown to be
superior to PTCA after recanalization of chronic total
occlusions, it was considered unethical to include occlusions
in the present trial.
Conclusions. Both balloon angioplasty and elective stent-
ing of discrete lesions in small coronary arteries are associ-
ated with favorable angiographic and clinical outcomes after
six months. Compared with PTCA, elective stenting using
the Hepamed-coated beStent does not improve the angio-
graphic outcome significantly, but it decreases the need for
repeat revascularization. The low restenosis rate in the stent
group might be related to the stent design, making this
device particularly useful in small vessels. The present results
might translate into a more liberal approach regarding
catheter-based treatment and stenting, in particular, of
small coronary arteries.
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